VRP.L Regulatory News (VRP)

Verona Pharma plc ("Verona Pharma" or the "Company") Verona Pharma to present at 7th Annual Biotech Showcase™ in San Francisco 12 January 2015, Cardiff - Verona Pharma plc (AIM: VRP.L), the drug developmentcompany focused on first-in-class medicines to treat respiratory diseases,announces that Company Chief Executive Officer, Dr Jan-Anders Karlsson, will bepresenting at the Biotech Showcase™ 2015 Conference, 12-14 January 2015, SanFrancisco, CA. Details of Verona Pharma's presentation are as follows: Event: Biotech Showcase™ 2015 Conference Date: 13 January 2015 Time: 16.30 PST Location: Room Mission II: Parc 55 Wyndham San Francisco Union Square Hotel Co-produced by Demy-Colton Life Science Advisors and EBD Group, BiotechShowcase is an investor and partnering conference devoted to providing privateand public biotechnology and life sciences companies an opportunity to presentto, and meet with, investors and pharmaceutical executives during the course ofone of the industry's largest annual healthcare investor conferences. Now inits seventh year, Biotech Showcase is expected to attract upwards of 1,500attendees. Further details on the presentations and timings can be accessed via thefollowing website: http://www.ebdgroup.com/bts/presenters/prs_comps.php -Ends- For further information please contact: Verona Pharma plc Tel: +44 (0) 20 3283 4200 Jan-Anders Karlsson, CEO FTI Consulting Tel: +44 (0)20 3727 1000 Julia Phillips / Simon Conway Notes to Editors About Verona Pharma plc Verona Pharma plc is a UK-based clinical stage biopharmaceutical companyfocused on the development of innovative prescription medicines to treatrespiratory diseases with significant unmet medical needs, such as chronicobstructive pulmonary disease (COPD), asthma and cystic fibrosis. Verona Pharma's lead drug, RPL554, is a first-in-class drug currently in PhaseII trials as a nebulised treatment for acute exacerbations of COPD in thehospital setting. The drug is a dual phosphodiesterase (PDE) 3/4 inhibitor andtherefore has both bronchodilator and anti-inflammatory effects, which areessential to the improvement of patients with COPD and asthma. Verona Pharma is also building a broader portfolio of RPL554-containingproducts to maximise its benefit to patients and its value. This includes thevery significant markets for COPD and asthma maintenance therapy. The Companyis also exploring the potential of the drug in different diseases, such ascystic fibrosis, where it is in pre-clinical testing and has recently receiveda Venture and Innovation Award from the Cystic Fibrosis Trust. About Demy-Colton Life Science Advisors Demy-Colton Life Science Advisors is focused exclusively on facilitating thegrowth of the life science industry. Now going into its fifth year, Demy-Coltonhas developed a number of high-value added conferences to address the businessand development needs of the biotechnology industry; it provides partneringservices and it has helped launch a unique investor website and newsletter. Formore information please visit www.demy-colton.com. About EBD Group EBD Group is the leading partnering firm for the global life science industry.Since 1993, biotech, pharma and medical device companies have leveraged EBDGroup's partnering conferences, technology and services to identify businessopportunities and develop strategic relationships essential to their success.For more information please visit www.ebdgroup.com or follow EBD Group onTwitter at twitter.com/ebdgroup.